Aurora Cannabis Inc. is engaged in the production, distribution, and sale of cannabis and cannabis derivative products both in Canada and internationally. The company's diverse operations encompass facility engineering and design, cannabis breeding, research, and production of various cannabis products, including dried cannabis, cannabis oil, capsules, and topical kits tailored for medical patients. It also offers vaporizers and consumable vaporizer accessories, alongside herb mills for CanniMed herbal cannabis products, grinders, and lockable containers for vaporizers. Additionally, Aurora Cannabis Inc. is involved in developing medical cannabis products that span multiple stages, including oral, topical, edible, and inhalable formats. The company operates CanvasRX, a network that provides cannabis counseling and outreach services. Its robust service offerings include patient counseling, design and construction services, and cannabis analytical product testing. The financial data pertains to the fiscal year 2025 during which the company reported a gross profit ratio of 0.55 reflecting the efficiency of its production and sales operations. The income before tax ratio is 0.06 indicating the company's pre-tax margin. The diluted EPS is $0.00 accounting for potential share dilution, while depreciation and amortization expenses amounted to $22,547,000.00 highlighting the wear and tear on its assets. The stock is affordable at $4.30 making it suitable for budget-conscious investors. With a market capitalization of $255,358,656.00 the company is classified as a small-cap player, positioned to impact the dynamics of the market. It is a key player in the Drug Manufacturers - Specialty & Generic industry, contributing significantly to the overall market landscape. Furthermore, the stock has an average trading volume of 1,186,867.00 indicating moderate liquidity. Aurora Cannabis Inc. belongs to the Healthcare sector, where it drives innovation and growth through its diverse range of products and services.